Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 370

1.

Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS).

Gralla RJ, Edelman MJ, Detterbeck FC, Jahan TM, Loesch DM, Limentani SA, Govindan R, Peng G, Monberg MJ, Obasaju CK, Socinski MA.

Support Care Cancer. 2009 Mar;17(3):307-13. doi: 10.1007/s00520-008-0489-y.

PMID:
18781341
2.

Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS).

Hollen PJ, Gralla RJ, Kris MG, Eberly SW, Cox C.

Support Care Cancer. 1999 May;7(3):140-8.

PMID:
10335932
3.

A dilemma in analysis: issues in the serial measurement of quality of life in patients with advanced lung cancer.

Hollen PJ, Gralla RJ, Cox C, Eberly SW, Kris MG.

Lung Cancer. 1997 Oct;18(2):119-36.

PMID:
9316004
4.
5.

Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale.

Hollen PJ, Gralla RJ, Kris MG, Cox C, Belani CP, Grunberg SM, Crawford J, Neidhart JA.

Cancer. 1994 Apr 15;73(8):2087-98.

7.

A retrospective quality of life analysis using the Lung Cancer Symptom Scale in patients treated with palliative radiotherapy for advanced nonsmall cell lung cancer.

Lutz ST, Huang DT, Ferguson CL, Kavanagh BD, Tercilla OF, Lu J.

Int J Radiat Oncol Biol Phys. 1997 Jan 1;37(1):117-22.

PMID:
9054885
8.

Adjuvant and neoadjuvant therapy for early-stage non-small-cell lung cancer.

Choong NW, Vokes EE.

Clin Lung Cancer. 2005 Dec;7 Suppl 3:S98-104. Review.

PMID:
16384544
9.

Continuous hyperfractionated accelerated radiation therapy week-end less in combination with neoadjuvant chemotherapy for the treatment of stage III non-small-cell lung cancer.

Bonomi M, Blanco-Savorio A, Cerchietti L, Navigante A, Castro M, Roth B, Wisnivesky JP.

Lung Cancer. 2008 Apr;60(1):75-82.

PMID:
17936404
10.

Resected non-small-cell lung cancer stage I/II: indication for adjuvant/neoadjuvant therapy?

Hoffmann H.

Lung Cancer. 2004 Aug;45 Suppl 2:S91-7. Review.

PMID:
15552788
11.
12.
13.

Gender differences in pretreatment quality of life in a prospective lung cancer trial.

Siddiqui F, Kohl R, Swann S, Watkins-Bruner D, Movsas B.

J Support Oncol. 2008 Jan;6(1):33-9.

PMID:
18257399
14.
15.
16.

Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: using the LCSS-Meso conceptual model for validation.

Hollen PJ, Gralla RJ, Liepa AM, Symanowski JT, Rusthoven JJ.

Cancer. 2004 Aug 1;101(3):587-95.

17.
18.

Quality of life during clinical trials: conceptual model for the Lung Cancer Symptom Scale (LCSS).

Hollen PJ, Gralla RJ, Kris MG, Cox C.

Support Care Cancer. 1994 Jul;2(4):213-22. Review.

PMID:
8087439
19.

Trimodality treatment in Stage III nonsmall cell lung carcinoma: prrognostic impact of K-ras mutations after neoadjuvant therapy.

Broermann P, Junker K, Brandt BH, Heinecke A, Freitag L, Klinke F, Berdel WE, Thomas M.

Cancer. 2002 Apr 1;94(7):2055-62.

20.

Initial prognostic factors in small-cell lung cancer patients predicting quality of life during chemotherapy. Swiss Group for Clinical Cancer Research (SAKK).

Bernhard J, Hürny C, Bacchi M, Joss RA, Cavalli F, Senn HJ, Leyvraz S, Stahel R, Ludwig C, Alberto P.

Br J Cancer. 1996 Nov;74(10):1660-7.

Supplemental Content

Support Center